Selumetinib
Mechanism :
Inhibits MEK (mitogen-activated extracellular kinase) protein kinases 1 and 2. It’s a part of a RAS regulated RAF-MEK-ERK pathway. Causing of this drug inhibited ERK phosphorylation creates reducced neurofibroma numbers, volume, and proliferation
Indication :
Contraindications :
No contraindications listed
Dosing :
For children ≥2 years with a body surface area of ≥0.55 m2 and adolescents – dosing based on body surface area - 25 mg/m2/dose administered twice a day
Adverse Effect :
Increased bleeding risk, Cardiomyopathy, increased creatinine phosphokinase levels, dermatologic toxicities, abdominal pain, constipation, nausea, blurred vision, cataract, photophobia, acute renal failure, increased serum alanine and aspartate transaminases, increased creatinine phosphokinase, fever, diarrhea
Interaction :
Antiplatelet agents may enhance the anti-platelet effect of Selumitinib
CYP3A4 inducers might reduce the concentration of the drug
CYP3A4 inhibitors might increase the concentration of the drug
Lactation :
Not enough data
Hepatic Dose :
Moderate hepatic impairment (Child Pugh B)- Reduce the dose to 20mg/m2 twice a day
Severe hepatic impairment (Child Pugh C)- No dose adjustments labelled
Pregnanacy :
May cause fetal harm